The timely and accurate diagnosis of prostate cancer is essential in catching it early, which emphasises the importance of reliable diagnostics. It is no surprise, then, that prostate cancer screening sales are worth approximately US$350 M annually, and that there have been a minimum of 60 prostate cancer diagnostic deals over the past 10 years, as recorded in PharmaDeals#174; Agreements. This feature examines the currently available tests, and some of those that are emerging, as well as the deals and companies concerning them, and also discusses the importance of discovering specific prostate cancer biomarkers.